ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1172

Cardiovascular involvement as a clue for diagnosis of Juvenile Systemic Sclerosis sine scleroderma
Abstract Number: 1179

Cardiovascular Risk Assessment with Carotid Ultrasonography in Addition to the Traditional Cardiovascular Risk Factor in Rheumatoid Arthritis: A Case Control Study
Abstract Number: 1993

Cardiovascular Risk in Rheumatoid Arthritis Patients Treated with Methotrexate versus Hydroxychloroquine
Abstract Number: 0927

Care Gap in Patients with Systemic Sclerosis with CXR Findings Suggestive of Fibrosis
Abstract Number: 1331

Carotid Ultrasound Findings in Psoriatic Arthritis: A Case-control Study
Abstract Number: 1108

Cartilage Biomarkers s-Coll2-1 and s-Coll2-1NO2 Are Associated with Knee Osteoarthritis MRI Features and Predict Disease Worsening
Abstract Number: 1318

Catastrophizing in Patients with Axial Spondyloarthritis and Psoriatic Arthritis
Abstract Number: 1968

Cathepsin S Gene Expression Measured in the Peripheral Blood of Osteoarthritic Patients Prior to Surgery as a Biomarker of Post-operative Pain Development
Abstract Number: 1984

Causal Pathways to Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the ReACCh-Out Cohort
Abstract Number: 0662

Cause-Specific Mortality in Patients with Gout in the Veteran’s Health Administration: A Matched Cohort Study
Abstract Number: 1949

CB2 Receptor Distribution and Effects of LenabasumTM in Dermatomyositis In Vitro
Abstract Number: 0098

CCL2 and CCR2 in Adult Onset Still’s Disease
Abstract Number: 0295

CCL3L3–null Status May Predispose to Systemic Lupus Erythematosus and Non-scarring Alopecia
Abstract Number: 0075

CD209+/CD14+ Dendritic Cells Characterization in Rheumatoid versus Psoriasis Arthritis Patients
Abstract Number: 1575

CD6 Is a Target for Cancer Immunotherapy

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].